Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20378894 | 0.90 | FFAR1 (0.46) | TSHRSMN1; SMN2HTTLMNAKMT2A | |
| SCHEMBL7708032 | 0.89 | TSHR (0.56) | TSHRSMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL20378909 | 0.88 | EPHX2 (0.50) | TSHRSMN1; SMN2HTTTDP1L3MBTL1 | |
| SCHEMBL20378787 | 0.87 | EPHX2 (0.52) | TSHRSMN1; SMN2HTTTDP1L3MBTL1 | |
| SCHEMBL15862001 | 0.84 | NPC1 (0.50) | TSHRSMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL28739368 | 0.84 | ALDH1A1 (0.52) | TSHRSMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL20379005 | 0.83 | GSK3B (0.42) | SMN1; SMN2ALDH1A1LMNATDP1MAPK1 | |
| SCHEMBL12655265 | 0.82 | TSHR (0.48) | TSHRSMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL8316692 | 0.82 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2HTTALDH1A1LMNA | |
| SCHEMBL24737439 | 0.81 | TSHR (0.52) | TSHRCPA1ALDH1A1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077671-A1 | POLYSUBSTITUTED ARYL DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20180201592-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2018-07-19 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2349996-A1 | 1-PHENYLPYRROLE COMPOUNDS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | REN, AGTR1, NR3C2 | TSHR 949/4885SMN1; SMN2 4592/4885HTT 4635/4885 |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | TSHR 168/4885SMN1; SMN2 2953/4885HTT 4619/4885 |
| US-20180201592-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | NAT1, DPM1, IL4I1 | TSHR 4424/4885SMN1; SMN2 2798/4885HTT 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.